| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ethanol | 109 | 2023 | 892 | 12.110 |
Why?
|
| Alcohol Drinking | 48 | 2023 | 805 | 9.260 |
Why?
|
| Alcoholism | 43 | 2023 | 1109 | 5.980 |
Why?
|
| Substance Withdrawal Syndrome | 32 | 2020 | 435 | 4.320 |
Why?
|
| Central Nervous System Depressants | 23 | 2018 | 182 | 3.740 |
Why?
|
| Binge Drinking | 5 | 2021 | 50 | 2.730 |
Why?
|
| Oxytocin | 5 | 2021 | 124 | 2.550 |
Why?
|
| Behavior, Animal | 16 | 2020 | 470 | 2.540 |
Why?
|
| Mice | 99 | 2023 | 8474 | 2.470 |
Why?
|
| Stress, Psychological | 14 | 2021 | 824 | 2.410 |
Why?
|
| Mice, Inbred C57BL | 63 | 2021 | 2791 | 2.400 |
Why?
|
| Receptors, Opioid, kappa | 5 | 2022 | 37 | 2.260 |
Why?
|
| Animals | 131 | 2023 | 20880 | 2.230 |
Why?
|
| Dynorphins | 4 | 2022 | 69 | 2.040 |
Why?
|
| Brain | 23 | 2020 | 2176 | 2.020 |
Why?
|
| Central Amygdaloid Nucleus | 3 | 2022 | 16 | 1.580 |
Why?
|
| Nucleus Accumbens | 11 | 2021 | 417 | 1.320 |
Why?
|
| Swimming | 4 | 2019 | 38 | 1.270 |
Why?
|
| Stress, Physiological | 4 | 2020 | 215 | 1.240 |
Why?
|
| Motivation | 4 | 2018 | 561 | 1.210 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2019 | 124 | 1.190 |
Why?
|
| Male | 90 | 2021 | 37283 | 1.160 |
Why?
|
| Prefrontal Cortex | 10 | 2020 | 639 | 1.160 |
Why?
|
| Disease Models, Animal | 13 | 2022 | 2550 | 1.100 |
Why?
|
| Self Administration | 9 | 2020 | 419 | 1.060 |
Why?
|
| Alcohol Withdrawal Seizures | 4 | 2011 | 12 | 1.030 |
Why?
|
| Receptors, Oxytocin | 2 | 2021 | 9 | 0.950 |
Why?
|
| Inhalation Exposure | 5 | 2016 | 33 | 0.920 |
Why?
|
| Models, Animal | 4 | 2019 | 252 | 0.920 |
Why?
|
| Conditioning, Operant | 9 | 2019 | 241 | 0.870 |
Why?
|
| Mice, Inbred C3H | 22 | 2011 | 134 | 0.860 |
Why?
|
| Dose-Response Relationship, Drug | 20 | 2018 | 1745 | 0.850 |
Why?
|
| Recurrence | 10 | 2021 | 948 | 0.820 |
Why?
|
| Behavior, Addictive | 4 | 2020 | 317 | 0.810 |
Why?
|
| Narcotic Antagonists | 3 | 2020 | 184 | 0.740 |
Why?
|
| Doxazosin | 1 | 2020 | 20 | 0.730 |
Why?
|
| Septal Nuclei | 1 | 2020 | 31 | 0.710 |
Why?
|
| Kindling, Neurologic | 7 | 1998 | 24 | 0.670 |
Why?
|
| Discrimination Learning | 5 | 2006 | 45 | 0.670 |
Why?
|
| Drug Tolerance | 4 | 2020 | 80 | 0.670 |
Why?
|
| 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 1 | 2018 | 5 | 0.670 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2019 | 114 | 0.660 |
Why?
|
| Naltrexone | 2 | 2018 | 195 | 0.650 |
Why?
|
| Gene Regulatory Networks | 6 | 2020 | 94 | 0.630 |
Why?
|
| Drinking Behavior | 3 | 2016 | 20 | 0.630 |
Why?
|
| Electroencephalography | 3 | 2006 | 418 | 0.630 |
Why?
|
| Motor Activity | 10 | 2011 | 621 | 0.620 |
Why?
|
| Orexins | 1 | 2018 | 52 | 0.610 |
Why?
|
| Neuronal Plasticity | 6 | 2020 | 274 | 0.580 |
Why?
|
| MicroRNAs | 2 | 2019 | 447 | 0.570 |
Why?
|
| Benzodiazepines | 8 | 1996 | 130 | 0.560 |
Why?
|
| Seizures | 10 | 2008 | 279 | 0.550 |
Why?
|
| Piperidines | 2 | 2018 | 123 | 0.550 |
Why?
|
| Lorazepam | 3 | 2009 | 54 | 0.550 |
Why?
|
| Orexin Receptor Antagonists | 1 | 2016 | 3 | 0.540 |
Why?
|
| Aminopyridines | 1 | 2016 | 26 | 0.540 |
Why?
|
| Glutamic Acid | 3 | 2014 | 332 | 0.530 |
Why?
|
| gamma-Aminobutyric Acid | 4 | 2018 | 208 | 0.530 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 137 | 0.520 |
Why?
|
| Azides | 7 | 1996 | 56 | 0.520 |
Why?
|
| Temperance | 3 | 2011 | 41 | 0.520 |
Why?
|
| Substance-Related Disorders | 3 | 2020 | 1242 | 0.510 |
Why?
|
| Hippocampus | 6 | 2019 | 471 | 0.490 |
Why?
|
| Microinjections | 4 | 2020 | 130 | 0.480 |
Why?
|
| Alcohol-Related Disorders | 1 | 2015 | 95 | 0.470 |
Why?
|
| Pyridines | 2 | 2013 | 261 | 0.470 |
Why?
|
| Precision Medicine | 1 | 2015 | 111 | 0.460 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2013 | 28 | 0.460 |
Why?
|
| Brain Chemistry | 2 | 2014 | 173 | 0.460 |
Why?
|
| Extracellular Fluid | 1 | 2013 | 29 | 0.460 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 5 | 2012 | 266 | 0.460 |
Why?
|
| Avoidance Learning | 4 | 2012 | 58 | 0.440 |
Why?
|
| Polydipsia | 1 | 2013 | 1 | 0.440 |
Why?
|
| Fetal Alcohol Spectrum Disorders | 6 | 1996 | 27 | 0.440 |
Why?
|
| Excitatory Amino Acid Antagonists | 4 | 2009 | 128 | 0.430 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2013 | 64 | 0.420 |
Why?
|
| Anticonvulsants | 2 | 2006 | 223 | 0.420 |
Why?
|
| Amino Acids | 2 | 2013 | 131 | 0.410 |
Why?
|
| Affect | 3 | 2022 | 218 | 0.410 |
Why?
|
| Neurons | 5 | 2021 | 881 | 0.410 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 3 | 2020 | 27 | 0.400 |
Why?
|
| GABA Modulators | 2 | 2005 | 26 | 0.400 |
Why?
|
| Social Isolation | 2 | 2010 | 40 | 0.390 |
Why?
|
| Dopamine | 4 | 2016 | 474 | 0.390 |
Why?
|
| Abnormalities, Drug-Induced | 8 | 1996 | 34 | 0.380 |
Why?
|
| Synapses | 4 | 2012 | 222 | 0.380 |
Why?
|
| Species Specificity | 6 | 2016 | 302 | 0.370 |
Why?
|
| Analysis of Variance | 10 | 2016 | 1040 | 0.350 |
Why?
|
| Female | 41 | 2020 | 38021 | 0.350 |
Why?
|
| Axons | 2 | 2015 | 139 | 0.350 |
Why?
|
| Receptors, Muscarinic | 1 | 2009 | 44 | 0.340 |
Why?
|
| Gene Expression | 1 | 2011 | 770 | 0.330 |
Why?
|
| Prenatal Exposure Delayed Effects | 7 | 1995 | 154 | 0.320 |
Why?
|
| Receptors, Metabotropic Glutamate | 2 | 2008 | 75 | 0.320 |
Why?
|
| Humans | 29 | 2023 | 68549 | 0.310 |
Why?
|
| Radiation Dosage | 1 | 2010 | 419 | 0.300 |
Why?
|
| Mice, Inbred DBA | 6 | 2016 | 120 | 0.300 |
Why?
|
| Dizocilpine Maleate | 2 | 2008 | 43 | 0.290 |
Why?
|
| Administration, Inhalation | 6 | 2020 | 187 | 0.290 |
Why?
|
| Alcoholic Intoxication | 5 | 2006 | 61 | 0.280 |
Why?
|
| Reinforcement Schedule | 3 | 2014 | 59 | 0.280 |
Why?
|
| Transcriptome | 2 | 2020 | 164 | 0.270 |
Why?
|
| Pregnancy | 23 | 2009 | 2334 | 0.270 |
Why?
|
| Rats | 19 | 2013 | 5300 | 0.270 |
Why?
|
| Drug-Seeking Behavior | 2 | 2020 | 213 | 0.270 |
Why?
|
| Computational Biology | 4 | 2020 | 190 | 0.270 |
Why?
|
| Body Weight | 12 | 2002 | 554 | 0.260 |
Why?
|
| Anti-Anxiety Agents | 3 | 1991 | 107 | 0.260 |
Why?
|
| RNA, Messenger | 2 | 2022 | 1663 | 0.260 |
Why?
|
| Microdialysis | 3 | 2013 | 147 | 0.260 |
Why?
|
| Heart | 1 | 2010 | 850 | 0.260 |
Why?
|
| Teratogens | 3 | 1996 | 11 | 0.260 |
Why?
|
| Alcohol Withdrawal Delirium | 2 | 1996 | 24 | 0.250 |
Why?
|
| Anxiety | 6 | 2022 | 422 | 0.240 |
Why?
|
| Synaptic Transmission | 5 | 2020 | 236 | 0.240 |
Why?
|
| Time Factors | 11 | 2016 | 4655 | 0.230 |
Why?
|
| Pregnanolone | 3 | 2014 | 6 | 0.230 |
Why?
|
| Pyrazoles | 3 | 2019 | 190 | 0.230 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2023 | 4 | 0.220 |
Why?
|
| Mice, Inbred Strains | 5 | 2014 | 181 | 0.220 |
Why?
|
| Psoriasis | 1 | 2023 | 46 | 0.210 |
Why?
|
| Reward | 2 | 2017 | 201 | 0.200 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 2021 | 15 | 0.200 |
Why?
|
| Hypothalamus | 1 | 2021 | 78 | 0.190 |
Why?
|
| Ceftriaxone | 1 | 2021 | 32 | 0.190 |
Why?
|
| Quinazolines | 1 | 2021 | 70 | 0.190 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2021 | 26 | 0.190 |
Why?
|
| Consummatory Behavior | 5 | 1992 | 8 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 2324 | 0.180 |
Why?
|
| Cerebral Cortex | 3 | 2008 | 415 | 0.180 |
Why?
|
| Corpus Striatum | 2 | 2019 | 278 | 0.180 |
Why?
|
| Dopaminergic Neurons | 2 | 2018 | 46 | 0.170 |
Why?
|
| Sucrose | 4 | 2016 | 58 | 0.170 |
Why?
|
| Convulsants | 1 | 1998 | 4 | 0.160 |
Why?
|
| Genetic Techniques | 1 | 2018 | 32 | 0.160 |
Why?
|
| Indomethacin | 3 | 1990 | 107 | 0.160 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2018 | 24 | 0.160 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1998 | 18 | 0.160 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2018 | 68 | 0.150 |
Why?
|
| Ventral Tegmental Area | 1 | 2018 | 74 | 0.150 |
Why?
|
| Gene Expression Regulation | 4 | 2016 | 1293 | 0.150 |
Why?
|
| Genetic Vectors | 1 | 2018 | 311 | 0.150 |
Why?
|
| Gestational Age | 3 | 1996 | 389 | 0.150 |
Why?
|
| Prostaglandins E | 4 | 1991 | 54 | 0.150 |
Why?
|
| Psychomotor Performance | 2 | 2011 | 213 | 0.150 |
Why?
|
| Fetal Death | 4 | 1996 | 49 | 0.150 |
Why?
|
| Neurotransmitter Agents | 2 | 2016 | 102 | 0.150 |
Why?
|
| Multiprotein Complexes | 1 | 2017 | 56 | 0.150 |
Why?
|
| Social Behavior | 1 | 2018 | 164 | 0.150 |
Why?
|
| Extinction, Psychological | 1 | 2019 | 240 | 0.150 |
Why?
|
| Pregnenolone | 1 | 2016 | 4 | 0.140 |
Why?
|
| Allostasis | 1 | 2016 | 6 | 0.140 |
Why?
|
| Protein Array Analysis | 1 | 2016 | 32 | 0.140 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 118 | 0.140 |
Why?
|
| Receptors, GABA-A | 5 | 2009 | 89 | 0.140 |
Why?
|
| Cocaine | 3 | 1996 | 555 | 0.140 |
Why?
|
| Alcohol-Induced Disorders, Nervous System | 1 | 2016 | 11 | 0.140 |
Why?
|
| Corticotropin-Releasing Hormone | 2 | 2018 | 79 | 0.140 |
Why?
|
| Locomotion | 1 | 2017 | 135 | 0.140 |
Why?
|
| Potassium Channels | 1 | 2016 | 55 | 0.140 |
Why?
|
| Diazepam | 1 | 1996 | 23 | 0.140 |
Why?
|
| Pharmacogenetics | 1 | 2016 | 47 | 0.130 |
Why?
|
| Drug Administration Schedule | 2 | 2008 | 567 | 0.130 |
Why?
|
| Rats, Inbred Strains | 10 | 1992 | 532 | 0.130 |
Why?
|
| Calpain | 2 | 2015 | 205 | 0.130 |
Why?
|
| Restraint, Physical | 1 | 2016 | 59 | 0.130 |
Why?
|
| Spinal Cord | 2 | 2015 | 244 | 0.130 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2015 | 20 | 0.130 |
Why?
|
| Apomorphine | 1 | 1995 | 48 | 0.130 |
Why?
|
| Cerebellum | 1 | 1996 | 103 | 0.130 |
Why?
|
| Globus Pallidus | 1 | 2015 | 64 | 0.130 |
Why?
|
| Urethral Stricture | 1 | 1995 | 19 | 0.120 |
Why?
|
| Dipeptides | 1 | 2015 | 89 | 0.120 |
Why?
|
| Laser Therapy | 1 | 1995 | 54 | 0.120 |
Why?
|
| Nerve Degeneration | 1 | 2015 | 134 | 0.120 |
Why?
|
| Urethra | 1 | 1995 | 56 | 0.120 |
Why?
|
| Withholding Treatment | 1 | 2014 | 35 | 0.120 |
Why?
|
| Alcohol Deterrents | 2 | 2020 | 86 | 0.120 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2012 | 150 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 176 | 0.120 |
Why?
|
| Pituitary-Adrenal System | 2 | 2012 | 138 | 0.120 |
Why?
|
| Electrophysiology | 2 | 2005 | 160 | 0.120 |
Why?
|
| Biogenic Amines | 1 | 2014 | 15 | 0.120 |
Why?
|
| Catecholamines | 1 | 1993 | 73 | 0.120 |
Why?
|
| Glycoproteins | 1 | 2015 | 238 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2016 | 2356 | 0.110 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2013 | 20 | 0.110 |
Why?
|
| Up-Regulation | 2 | 2011 | 682 | 0.110 |
Why?
|
| Patch-Clamp Techniques | 4 | 2015 | 204 | 0.110 |
Why?
|
| Aspartic Acid | 1 | 2013 | 65 | 0.110 |
Why?
|
| Arousal | 1 | 1993 | 168 | 0.110 |
Why?
|
| Pregnancy, Animal | 3 | 1990 | 27 | 0.110 |
Why?
|
| Neural Pathways | 1 | 2015 | 323 | 0.110 |
Why?
|
| Rodentia | 1 | 2013 | 27 | 0.110 |
Why?
|
| Excitatory Postsynaptic Potentials | 3 | 2020 | 87 | 0.110 |
Why?
|
| Motor Neurons | 1 | 2013 | 98 | 0.110 |
Why?
|
| Neuroprotective Agents | 1 | 2015 | 317 | 0.100 |
Why?
|
| Uterus | 2 | 1990 | 77 | 0.100 |
Why?
|
| Reversal Learning | 1 | 2011 | 7 | 0.100 |
Why?
|
| Reflex, Righting | 1 | 2011 | 4 | 0.100 |
Why?
|
| Receptors, Notch | 1 | 2011 | 15 | 0.100 |
Why?
|
| Genes, ras | 1 | 2011 | 46 | 0.100 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2011 | 43 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2013 | 954 | 0.100 |
Why?
|
| Norepinephrine | 1 | 2012 | 276 | 0.100 |
Why?
|
| Aspirin | 7 | 1992 | 295 | 0.100 |
Why?
|
| Weaning | 1 | 2010 | 12 | 0.090 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 2 | 2008 | 51 | 0.090 |
Why?
|
| Picrotoxin | 1 | 1990 | 14 | 0.090 |
Why?
|
| Ubiquitin | 1 | 2011 | 74 | 0.090 |
Why?
|
| Stereotyped Behavior | 2 | 1987 | 42 | 0.090 |
Why?
|
| Prostaglandins | 2 | 1989 | 65 | 0.090 |
Why?
|
| Injections, Intraperitoneal | 2 | 2006 | 89 | 0.090 |
Why?
|
| Circadian Rhythm | 1 | 2011 | 218 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2012 | 186 | 0.090 |
Why?
|
| Frontal Lobe | 1 | 2011 | 156 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 247 | 0.090 |
Why?
|
| Actins | 1 | 2011 | 249 | 0.090 |
Why?
|
| Valproic Acid | 1 | 1990 | 93 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2011 | 447 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 710 | 0.090 |
Why?
|
| Tetrazolium Salts | 1 | 2009 | 36 | 0.090 |
Why?
|
| Carbachol | 1 | 2009 | 34 | 0.090 |
Why?
|
| Muscarinic Agonists | 1 | 2009 | 17 | 0.090 |
Why?
|
| Culture Media, Conditioned | 1 | 2009 | 78 | 0.090 |
Why?
|
| Phenotype | 2 | 2010 | 946 | 0.090 |
Why?
|
| Receptor, Muscarinic M1 | 1 | 2009 | 17 | 0.090 |
Why?
|
| Coloring Agents | 1 | 2009 | 66 | 0.080 |
Why?
|
| Body Temperature | 3 | 1997 | 116 | 0.080 |
Why?
|
| Central Nervous System Stimulants | 1 | 2011 | 221 | 0.080 |
Why?
|
| Thiazoles | 1 | 2009 | 95 | 0.080 |
Why?
|
| Affinity Labels | 1 | 1989 | 66 | 0.080 |
Why?
|
| Adaptation, Physiological | 1 | 2010 | 189 | 0.080 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2009 | 60 | 0.080 |
Why?
|
| Shab Potassium Channels | 1 | 2008 | 6 | 0.080 |
Why?
|
| Amino Acid Transport System X-AG | 1 | 2008 | 11 | 0.080 |
Why?
|
| Embryonic and Fetal Development | 2 | 1995 | 74 | 0.080 |
Why?
|
| Hypnotics and Sedatives | 1 | 2009 | 96 | 0.080 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 1033 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 175 | 0.080 |
Why?
|
| Amines | 1 | 2009 | 98 | 0.080 |
Why?
|
| Acute Disease | 1 | 2010 | 658 | 0.080 |
Why?
|
| Taurine | 1 | 2008 | 51 | 0.080 |
Why?
|
| In Vitro Techniques | 3 | 2016 | 765 | 0.080 |
Why?
|
| Embryo, Mammalian | 1 | 1988 | 176 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2008 | 282 | 0.080 |
Why?
|
| Protein Kinase C | 1 | 2009 | 270 | 0.080 |
Why?
|
| Hypothermia | 1 | 1988 | 37 | 0.080 |
Why?
|
| Rats, Long-Evans | 1 | 2008 | 203 | 0.080 |
Why?
|
| Drug Interactions | 4 | 2010 | 289 | 0.080 |
Why?
|
| Conditioning, Classical | 2 | 1984 | 57 | 0.070 |
Why?
|
| Rats, Wistar | 1 | 2008 | 371 | 0.070 |
Why?
|
| Fetus | 4 | 1994 | 157 | 0.070 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 420 | 0.070 |
Why?
|
| Chromatography, Gas | 1 | 2006 | 31 | 0.070 |
Why?
|
| Mice, Knockout | 1 | 2011 | 1692 | 0.070 |
Why?
|
| Cells, Cultured | 2 | 2009 | 2673 | 0.070 |
Why?
|
| Astrocytes | 1 | 2009 | 270 | 0.070 |
Why?
|
| Insulin | 3 | 1984 | 617 | 0.070 |
Why?
|
| Osmolar Concentration | 1 | 2006 | 134 | 0.070 |
Why?
|
| Chlordiazepoxide | 2 | 1984 | 2 | 0.070 |
Why?
|
| Volatilization | 1 | 2006 | 13 | 0.070 |
Why?
|
| Sex Factors | 1 | 2010 | 1265 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1174 | 0.070 |
Why?
|
| Taste | 2 | 1984 | 49 | 0.070 |
Why?
|
| Serotonin Antagonists | 1 | 1986 | 31 | 0.070 |
Why?
|
| Pregabalin | 1 | 2006 | 13 | 0.070 |
Why?
|
| Receptors, Neurotransmitter | 1 | 2006 | 31 | 0.070 |
Why?
|
| Hyperkinesis | 1 | 2005 | 8 | 0.070 |
Why?
|
| Ovariectomy | 1 | 1985 | 49 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 498 | 0.070 |
Why?
|
| Serotonin | 1 | 1986 | 144 | 0.070 |
Why?
|
| Feeding Behavior | 2 | 1984 | 224 | 0.070 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2006 | 100 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2005 | 238 | 0.060 |
Why?
|
| Electrodes | 1 | 2005 | 147 | 0.060 |
Why?
|
| Blood Glucose | 3 | 1984 | 631 | 0.060 |
Why?
|
| Generalization, Stimulus | 1 | 2004 | 5 | 0.060 |
Why?
|
| Receptors, AMPA | 2 | 2017 | 99 | 0.060 |
Why?
|
| Pentylenetetrazole | 2 | 2008 | 10 | 0.060 |
Why?
|
| Dendritic Spines | 2 | 2017 | 76 | 0.060 |
Why?
|
| Linear Models | 2 | 2016 | 521 | 0.060 |
Why?
|
| Reaction Time | 1 | 2004 | 170 | 0.060 |
Why?
|
| Maternal-Fetal Exchange | 3 | 1995 | 57 | 0.060 |
Why?
|
| Amygdala | 1 | 1984 | 159 | 0.050 |
Why?
|
| Thalidomide | 1 | 2023 | 24 | 0.050 |
Why?
|
| Attention | 2 | 2017 | 225 | 0.050 |
Why?
|
| Electrodes, Implanted | 1 | 2002 | 98 | 0.050 |
Why?
|
| Cues | 1 | 2006 | 654 | 0.050 |
Why?
|
| Alcohol Abstinence | 1 | 2022 | 23 | 0.050 |
Why?
|
| Random Allocation | 2 | 2020 | 442 | 0.050 |
Why?
|
| Mice, Mutant Strains | 2 | 2015 | 166 | 0.050 |
Why?
|
| Histones | 1 | 2021 | 111 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 848 | 0.040 |
Why?
|
| Cognition | 2 | 2015 | 512 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 163 | 0.040 |
Why?
|
| Organ Culture Techniques | 2 | 2010 | 122 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2009 | 147 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2017 | 617 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2020 | 141 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 106 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 426 | 0.040 |
Why?
|
| Receptors, Presynaptic | 1 | 2018 | 6 | 0.040 |
Why?
|
| Animals, Newborn | 2 | 2010 | 396 | 0.040 |
Why?
|
| Egtazic Acid | 1 | 2018 | 29 | 0.040 |
Why?
|
| Kainic Acid | 1 | 1998 | 44 | 0.040 |
Why?
|
| Weight Gain | 2 | 1996 | 135 | 0.040 |
Why?
|
| Benzoxazines | 1 | 2018 | 20 | 0.040 |
Why?
|
| Carbolines | 2 | 1989 | 19 | 0.040 |
Why?
|
| Flumazenil | 2 | 1989 | 23 | 0.040 |
Why?
|
| Age Factors | 2 | 2013 | 1860 | 0.040 |
Why?
|
| Naphthalenes | 1 | 2018 | 47 | 0.040 |
Why?
|
| Morpholines | 1 | 2018 | 79 | 0.040 |
Why?
|
| Genes, fos | 1 | 2017 | 22 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 32 | 0.040 |
Why?
|
| Actin Cytoskeleton | 1 | 2017 | 37 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2018 | 219 | 0.040 |
Why?
|
| 17-alpha-Hydroxypregnenolone | 1 | 2016 | 2 | 0.040 |
Why?
|
| Receptors, GABA | 1 | 1996 | 8 | 0.040 |
Why?
|
| Limbic System | 1 | 2017 | 106 | 0.040 |
Why?
|
| Phenylenediamines | 1 | 2016 | 16 | 0.040 |
Why?
|
| Ventral Striatum | 1 | 2016 | 5 | 0.030 |
Why?
|
| Sex Ratio | 1 | 1996 | 13 | 0.030 |
Why?
|
| Membrane Transport Modulators | 1 | 2016 | 23 | 0.030 |
Why?
|
| Environment | 3 | 2006 | 115 | 0.030 |
Why?
|
| Compulsive Behavior | 1 | 2016 | 12 | 0.030 |
Why?
|
| Carbamates | 1 | 2016 | 41 | 0.030 |
Why?
|
| Hematoma | 1 | 1996 | 47 | 0.030 |
Why?
|
| Obstetric Labor, Premature | 1 | 1996 | 76 | 0.030 |
Why?
|
| Steroids | 1 | 2016 | 84 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2016 | 220 | 0.030 |
Why?
|
| Learning | 1 | 2017 | 186 | 0.030 |
Why?
|
| Apamin | 1 | 2015 | 13 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2016 | 161 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 103 | 0.030 |
Why?
|
| Potassium Channel Blockers | 1 | 2015 | 32 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2015 | 35 | 0.030 |
Why?
|
| Functional Neuroimaging | 1 | 2015 | 82 | 0.030 |
Why?
|
| Myelin Sheath | 1 | 2015 | 115 | 0.030 |
Why?
|
| Urodynamics | 1 | 1995 | 43 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2015 | 63 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 167 | 0.030 |
Why?
|
| Clonidine | 1 | 1994 | 66 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2010 | 2083 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 320 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2015 | 85 | 0.030 |
Why?
|
| Alleles | 1 | 2015 | 386 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2017 | 597 | 0.030 |
Why?
|
| Binding Sites | 1 | 1996 | 631 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 170 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 2015 | 218 | 0.030 |
Why?
|
| Methyltyrosines | 1 | 1993 | 6 | 0.030 |
Why?
|
| alpha-Methyltyrosine | 1 | 1993 | 6 | 0.030 |
Why?
|
| Base Sequence | 1 | 2016 | 1015 | 0.030 |
Why?
|
| Drug Synergism | 2 | 1992 | 260 | 0.030 |
Why?
|
| Sex Characteristics | 2 | 1992 | 295 | 0.030 |
Why?
|
| Body Temperature Regulation | 1 | 1993 | 29 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 785 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 562 | 0.030 |
Why?
|
| Litter Size | 2 | 1995 | 14 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 517 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 282 | 0.030 |
Why?
|
| Emotions | 2 | 2004 | 244 | 0.030 |
Why?
|
| Chlorpromazine | 1 | 1992 | 7 | 0.030 |
Why?
|
| Peptides | 1 | 2015 | 455 | 0.030 |
Why?
|
| Haloperidol | 1 | 1992 | 95 | 0.030 |
Why?
|
| Protein Subunits | 1 | 2012 | 99 | 0.030 |
Why?
|
| United States | 2 | 2020 | 7338 | 0.020 |
Why?
|
| Ibuprofen | 1 | 1991 | 30 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 791 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1549 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 1593 | 0.020 |
Why?
|
| Propidium | 1 | 2010 | 26 | 0.020 |
Why?
|
| Calcium Channel Agonists | 1 | 2010 | 18 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 498 | 0.020 |
Why?
|
| DNA | 1 | 2013 | 597 | 0.020 |
Why?
|
| Thromboxane B2 | 1 | 1990 | 108 | 0.020 |
Why?
|
| Corticosterone | 1 | 2009 | 51 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2010 | 128 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2009 | 106 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 1118 | 0.020 |
Why?
|
| Disks Large Homolog 4 Protein | 1 | 2008 | 15 | 0.020 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2008 | 59 | 0.020 |
Why?
|
| N-Methylaspartate | 1 | 2008 | 59 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 1851 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2008 | 200 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 1989 | 206 | 0.020 |
Why?
|
| Chlorides | 1 | 1988 | 68 | 0.020 |
Why?
|
| Ion Channels | 1 | 1988 | 72 | 0.020 |
Why?
|
| Fertility | 1 | 1987 | 60 | 0.020 |
Why?
|
| Prostaglandins F | 1 | 1987 | 13 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 216 | 0.020 |
Why?
|
| Dinoprost | 1 | 1987 | 27 | 0.020 |
Why?
|
| Temperature | 1 | 1988 | 340 | 0.020 |
Why?
|
| Cricetinae | 1 | 1987 | 262 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2009 | 782 | 0.020 |
Why?
|
| Calcium | 1 | 2010 | 929 | 0.020 |
Why?
|
| Cinanserin | 1 | 1986 | 1 | 0.020 |
Why?
|
| Pyrilamine | 1 | 1986 | 1 | 0.020 |
Why?
|
| Cyproheptadine | 1 | 1986 | 6 | 0.020 |
Why?
|
| Methysergide | 1 | 1986 | 4 | 0.020 |
Why?
|
| Chick Embryo | 1 | 1987 | 379 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 2222 | 0.020 |
Why?
|
| Rabbits | 1 | 1987 | 509 | 0.020 |
Why?
|
| Haplorhini | 1 | 2006 | 44 | 0.020 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 1 | 2006 | 6 | 0.020 |
Why?
|
| Midazolam | 1 | 1986 | 46 | 0.020 |
Why?
|
| Risk | 1 | 1987 | 563 | 0.020 |
Why?
|
| Drinking | 1 | 1986 | 35 | 0.020 |
Why?
|
| Reflex | 1 | 1985 | 21 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2009 | 1738 | 0.020 |
Why?
|
| Adult | 2 | 2015 | 21379 | 0.010 |
Why?
|
| Pregnancy Outcome | 2 | 1995 | 157 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 5710 | 0.010 |
Why?
|
| Hunger | 1 | 1983 | 27 | 0.010 |
Why?
|
| Memory | 1 | 1984 | 214 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1995 | 7268 | 0.010 |
Why?
|
| Brain Mapping | 1 | 1984 | 531 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2004 | 403 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2009 | 7028 | 0.010 |
Why?
|
| Middle Aged | 1 | 2015 | 21119 | 0.010 |
Why?
|
| Eating | 1 | 1994 | 119 | 0.010 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 1994 | 152 | 0.010 |
Why?
|
| Flurazepam | 1 | 1992 | 1 | 0.010 |
Why?
|
| Urine | 1 | 1992 | 47 | 0.010 |
Why?
|
| Odorants | 1 | 1992 | 52 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1992 | 532 | 0.010 |
Why?
|
| Acetaldehyde | 1 | 1990 | 18 | 0.010 |
Why?
|
| Prostaglandin Antagonists | 1 | 1989 | 11 | 0.010 |
Why?
|
| Electroshock | 1 | 1989 | 36 | 0.010 |
Why?
|
| Habituation, Psychophysiologic | 1 | 1984 | 22 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1990 | 2455 | 0.000 |
Why?
|
| Food Deprivation | 1 | 1983 | 22 | 0.000 |
Why?
|